These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12842427)

  • 1. Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients.
    Bowman JE; Reese JS; Lingas KT; Gerson SL
    Mol Ther; 2003 Jul; 8(1):42-50. PubMed ID: 12842427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug selection of mutant methylguanine methyltransferase from different oncoretroviral backbones results in multilineage hematopoietic transgene expression in primary and secondary recipients.
    Davis BM; Reese JS; Lingas K; Gerson SL
    J Hematother Stem Cell Res; 2003 Aug; 12(4):375-87. PubMed ID: 12965075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells.
    Ragg S; Xu-Welliver M; Bailey J; D'Souza M; Cooper R; Chandra S; Seshadri R; Pegg AE; Williams DA
    Cancer Res; 2000 Sep; 60(18):5187-95. PubMed ID: 11016647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G156A MGMT-transduced human mesenchymal stem cells can be selectively enriched by O6-benzylguanine and BCNU.
    Lee K; Gerson SL; Maitra B; Koç ON
    J Hematother Stem Cell Res; 2001 Oct; 10(5):691-701. PubMed ID: 11672516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Davis BM; Reese JS; Koç ON; Lee K; Schupp JE; Gerson SL
    Cancer Res; 1997 Nov; 57(22):5093-9. PubMed ID: 9371508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy.
    Davis BM; Roth JC; Liu L; Xu-Welliver M; Pegg AE; Gerson SL
    Hum Gene Ther; 1999 Nov; 10(17):2769-78. PubMed ID: 10584923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning.
    Zielske SP; Reese JS; Lingas KT; Donze JR; Gerson SL
    J Clin Invest; 2003 Nov; 112(10):1561-70. PubMed ID: 14617757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts.
    Koç ON; Reese JS; Davis BM; Liu L; Majczenko KJ; Gerson SL
    Hum Gene Ther; 1999 Apr; 10(6):1021-30. PubMed ID: 10223735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
    Kreklau EL; Pollok KE; Bailey BJ; Liu N; Hartwell JR; Williams DA; Erickson LC
    Mol Cancer Ther; 2003 Dec; 2(12):1321-9. PubMed ID: 14707273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression.
    Ball CR; Pilz IH; Schmidt M; Fessler S; Williams DA; von Kalle C; Glimm H
    Blood; 2007 Sep; 110(6):1779-87. PubMed ID: 17496202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterisation of a P140K mutant O6-methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow.
    Kramer BA; Lemckert FA; Alexander IE; Gunning PW; McCowage GB
    J Gene Med; 2006 Sep; 8(9):1071-85. PubMed ID: 16927363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retroviral-mediated expression of the P140A, but not P140A/G156A, mutant form of O6-methylguanine DNA methyltransferase protects hematopoietic cells against O6-benzylguanine sensitization to chloroethylnitrosourea treatment.
    Maze R; Kurpad C; Pegg AE; Erickson LC; Williams DA
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1467-74. PubMed ID: 10454526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells.
    Jansen M; Sorg UR; Ragg S; Flasshove M; Seeber S; Williams DA; Moritz T
    Cancer Gene Ther; 2002 Sep; 9(9):737-46. PubMed ID: 12189523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells.
    Fontes AM; Davis BM; Encell LP; Lingas K; Covas DT; Zago MA; Loeb LA; Pegg AE; Gerson SL
    Mol Cancer Ther; 2006 Jan; 5(1):121-8. PubMed ID: 16432170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene.
    Larochelle A; Choi U; Shou Y; Naumann N; Loktionova NA; Clevenger JR; Krouse A; Metzger M; Donahue RE; Kang E; Stewart C; Persons D; Malech HL; Dunbar CE; Sorrentino BP
    J Clin Invest; 2009 Jul; 119(7):1952-63. PubMed ID: 19509470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine.
    Woolford LB; Southgate TD; Margison GP; Milsom MD; Fairbairn LJ
    J Gene Med; 2006 Jan; 8(1):29-34. PubMed ID: 16075413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limiting numbers of G156A O(6)-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection.
    Davis BM; Koç ON; Gerson SL
    Blood; 2000 May; 95(10):3078-84. PubMed ID: 10807772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector.
    Sawai N; Zhou S; Vanin EF; Houghton P; Brent TP; Sorrentino BP
    Mol Ther; 2001 Jan; 3(1):78-87. PubMed ID: 11162314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro.
    Zielske SP; Gerson SL
    Mol Ther; 2002 Apr; 5(4):381-7. PubMed ID: 11945064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide.
    Reese JS; Davis BM; Liu L; Gerson SL
    Clin Cancer Res; 1999 Jan; 5(1):163-9. PubMed ID: 9918215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.